Pharmacyclics Inc. (PCYC)
-NasdaqCM | Prev Close: | 84.70 |
|---|
| Open: | N/A |
|---|
| Bid: | 70.31 x 200 |
|---|
| Ask: | 92.12 x 100 |
|---|
| 1y Target Est: | 100.80 |
|---|
| Beta: | 0.78 |
|---|
| Next Earnings Date: | 6-Sep-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 44.88 - 95.85 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 730,638 |
|---|
| Market Cap: | 6.16B |
|---|
| P/E (ttm): | 128.92 |
|---|
| EPS (ttm): | 0.66 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Pharmacyclics: Ibrutinib Phase 2 study results in patients with mantle cell lymphoma published in The New England Journal of MedicineBriefing.com(Thu, 14:43 SGT)
- Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of MedicinePR Newswire(Thu, 10:02 SGT)
- 3 Blood Cancer Drug Hopefuls in the Spotlightat Motley Fool(Thu, 07:11 SGT)
- Pharmacyclics reports positive results from Phase 1b/2 study of Ibrutinibat theflyonthewall.com(Thu, 05:55 SGT)
- Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of MedicinePR Newswire(Thu, 05:51 SGT)
- Pharmacyclics data positive, says JMP Securitiestheflyonthewall.com(Wed, 19 Jun)
- PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, 19 Jun)
- PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Tue, 18 Jun)
- PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, 17 Jun)
- Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell LymphomaPR Newswire(Sun, 16 Jun)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| PCYC | 0.00% | 6.16B |
| NVO | 0.00% | 85.98B |
| TEVA | 0.00% | 33.48B |
| AGN | 0.00% | 29.43B |
| FRX | 0.00% | 11.16B |
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 37.22 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.90 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | -603.06 |
|---|
Business Summary
Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases.
View More